Möchten Sie immer auf dem neuesten Stand bleiben?

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and...

Issued on behalf of Sky Quarry, Inc. A small-cap operator with a 5,000-bpd refinery just signed a multi-party MOU with two clean-fuel partners — and the move suggests the next chapter of the SAF...

EDEN PRAIRIE, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Arctic Wolf®, the cybersecurity and AI company, today announced Aurora® Exposure Management, a new family of products designed to help...

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, announced the appointment of Bhupender Singh as president and head of international growth markets. He...

Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of...

Phase 3 ARISE trial of solengepras, a potential first-in-class non-dopaminergic therapy, is fully enrolled and topline data is expected at the end of Q3 2026Pivotal study targets daily OFF periods, a...

LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...

Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with...

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Satellogic Reports First Quarter 2026 Financial Results